PathMaker Neurosystems Announces Initiation of First-in-Human Trial in ALS for Non-Invasive Neuromodulation Device
September 14, 2023 06:00 ET
|
PathMaker Neurosystems Inc.
BOSTON and PARIS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the...
Global Amyotrophic Lateral Sclerosis Market Size to Reach USD 1,034.7 Million in 2032 | Emergen Research
August 29, 2023 08:56 ET
|
Emergen Research
Vancouver, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The worldwide market for amyotrophic lateral sclerosis achieved a size of USD 613.0 million in the year 2022. According to the most recent study...
Amyotrophic Lateral Sclerosis Treatment Market to Surpass 138.58 Million by 2030 Drives Due to the Availability of Improved Healthcare Expenditure
July 27, 2023 09:15 ET
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford USA, July 27, 2023 (GLOBE NEWSWIRE) -- According to SkyQuest, the rise in the prevalence of amyotrophic lateral sclerosis treatment market has driven a surge in demand for effective...
Amyotrophic Lateral Sclerosis Market to Surge Immensely by 2032, Predicts DelveInsight | Key Companies to Watch Out - Cytokinetics, Orphazyme, Orion, Biogen, AB Science, Ionis, Biohaven, MediciNova, NeuroSense
July 19, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 19, 2023 (GLOBE NEWSWIRE) -- Amyotrophic Lateral Sclerosis Market to Surge Immensely by 2032, Predicts DelveInsight | Key Companies to Watch Out - Cytokinetics, Orphazyme, Orion,...
Amyotrophic Lateral Sclerosis Treatment Market to Reach US$ 594.1 Million in 2031, Expanding at a CAGR of 5.5%: TMR Report
June 26, 2023 13:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, June 26, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. – In 2022, the global industry was estimated to be worth $594.1 million. It is expected to...
PathMaker Neurosystems Receives $200,000 START Award from MassVentures
June 05, 2023 06:00 ET
|
PathMaker Neurosystems Inc.
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of...
AB Science résume les messages clés de sa participation à une table ronde lors du ALS Drug Development Summit 2023
May 17, 2023 14:15 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE RÉSUME LES MESSAGES CLÉS DE SA PARTICIPATION À UNE TABLE RONDE LORS DU ALS DRUG DEVELOPMENT SUMMIT 2023 (BOSTON, ETATS-UNIS) Paris, 17 mai 2023, 20h00 AB Science SA...
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
May 17, 2023 14:15 ET
|
AB Science
PRESS RELEASE AB SCIENCE SUMMARIZES KEY MESSAGES FROM ITS PARTICIPATION TO A PANEL DISCUSSION AT THE 2023 ALS DRUG DEVELOPMENT SUMMIT (BOSTON, USA) Paris, 17 May, 2023, 8:00pm CET AB Science SA...
AB Science annonce que Health Canada a repris la revue du dossier d’enregistrement du masitinib dans la sclérose latérale amyotrophique, suite à l’examen préliminaire de la réponse soumise par AB Science
May 09, 2023 12:06 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE QUE HEALTH CANADA A REPRIS LA REVUE DU DOSSIER D’ENREGISTREMENT DU MASITINIB DANS LA SCLEROSE LATERALE AMYOTROPHIQUE, SUITE A L’EXAMEN PRELIMINAIRE DE LA...
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
May 09, 2023 12:06 ET
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS RESUMED ITS REVIEW OF THE NEW DRUG SUBMISSION FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS, FOLLOWING ISSUANCE OF A SCREENING ACCEPTANCE...